SOPHiA GENETICS SA $SOPH Shares Newly Bought by Sowell Financial Services LLC

Sowell Financial Services LLC acquired a new position in SOPHiA GENETICS SA (NASDAQ:SOPH) during the 3rd quarter, Holdings Channel reports. The firm acquired 341,889 shares of the company’s stock, valued at approximately $2,865,000.

Several other large investors also recently added to or reduced their stakes in SOPH. Maven Securities LTD purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter worth $866,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the 2nd quarter worth $9,809,000. Sei Investments Co. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter worth $1,772,000. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the 2nd quarter worth $567,000. Finally, Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS in the 1st quarter worth $2,157,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH opened at $7.63 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $640.12 million, a P/E ratio of -6.63 and a beta of 0.95. SOPHiA GENETICS SA has a 12 month low of $3.83 and a 12 month high of $8.98. The business’s 50-day moving average is $7.87 and its 200 day moving average is $5.95.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SOPH has been the subject of a number of analyst reports. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, October 15th. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, October 12th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus price target of $10.00.

Insider Activity at SOPHiA GENETICS

In other news, Chairman Jurgi Camblong sold 40,172 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $326,598.36. Following the sale, the chairman directly owned 3,395,650 shares in the company, valued at approximately $27,606,634.50. This represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ross Muken sold 9,838 shares of SOPHiA GENETICS stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.13, for a total value of $79,982.94. Following the sale, the chief executive officer owned 660,391 shares of the company’s stock, valued at approximately $5,368,978.83. This trade represents a 1.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 250,662 shares of company stock worth $1,942,499. Insiders own 4.88% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.